187 related articles for article (PubMed ID: 8807467)
21. Aldose reductase inhibition alters nodal Na+ currents and nerve conduction in human diabetics.
Misawa S; Kuwabara S; Kanai K; Tamura N; Nakata M; Sawai S; Yagui K; Hattori T
Neurology; 2006 May; 66(10):1545-9. PubMed ID: 16717216
[TBL] [Abstract][Full Text] [Related]
22. The role of cyclic adenosine 3',5'-monophosphate and polyol metabolism in diabetic neuropathy.
Shindo H; Tawata M; Aida K; Onaya T
J Clin Endocrinol Metab; 1992 Feb; 74(2):393-8. PubMed ID: 1370506
[TBL] [Abstract][Full Text] [Related]
23. The absence of synergism between the effects of an aldose reductase inhibitor, epalrestat, and a vasodilator, cilostazol, on the nerve conduction slowing and the myelinated fiber atrophy in streptozotocin-induced diabetic rats.
Sasaki H; Naka K; Kishi Y; Furuta M; Sanke T; Mukoyama M; Nanjo K
Exp Neurol; 1997 Aug; 146(2):466-70. PubMed ID: 9270057
[TBL] [Abstract][Full Text] [Related]
24. The aldose reductase inhibitor epalrestat exerts nephritic protection on diabetic nephropathy in db/db mice through metabolic modulation.
He J; Gao HX; Yang N; Zhu XD; Sun RB; Xie Y; Zeng CH; Zhang JW; Wang JK; Ding F; Aa JY; Wang GJ
Acta Pharmacol Sin; 2019 Jan; 40(1):86-97. PubMed ID: 29930278
[TBL] [Abstract][Full Text] [Related]
25. Aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy: a review.
Schemmel KE; Padiyara RS; D'Souza JJ
J Diabetes Complications; 2010; 24(5):354-60. PubMed ID: 19748287
[TBL] [Abstract][Full Text] [Related]
26. Reproducibility of parameters for assessment of diabetic neuropathy. The French Group for Research and Study of Diabetic Neuropathy.
Valensi P; Attali JR; Gagant S
Diabet Med; 1993 Dec; 10(10):933-9. PubMed ID: 8306589
[TBL] [Abstract][Full Text] [Related]
27. Natural progression of diabetic peripheral neuropathy in the Zenarestat study population.
Brown MJ; Bird SJ; Watling S; Kaleta H; Hayes L; Eckert S; Foyt HL;
Diabetes Care; 2004 May; 27(5):1153-9. PubMed ID: 15111537
[TBL] [Abstract][Full Text] [Related]
28. Effects of aldose reductase inhibitor on microneurographically assessed peripheral sympathetic nerve activity in rats.
Sato D; Kusunoki M; Shinzawa G; Feng Z; Nishina A; Nakamura T
Auton Neurosci; 2015 Dec; 193():69-73. PubMed ID: 26272532
[TBL] [Abstract][Full Text] [Related]
29. Epalrestat, an aldose reductase ihibitor, reduces the levels of Nepsilon-(carboxymethyl)lysine protein adducts and their precursors in erythrocytes from diabetic patients.
Hamada Y; Nakamura J; Naruse K; Komori T; Kato K; Kasuya Y; Nagai R; Horiuchi S; Hotta N
Diabetes Care; 2000 Oct; 23(10):1539-44. PubMed ID: 11023149
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic effects of aldose reductase inhibitor on experimental diabetic neuropathy through synthesis/secretion of nerve growth factor.
Ohi T; Saita K; Furukawa S; Ohta M; Hayashi K; Matsukura S
Exp Neurol; 1998 Jun; 151(2):215-20. PubMed ID: 9628756
[TBL] [Abstract][Full Text] [Related]
31. Long-term effect of epalrestat on cardiac autonomic neuropathy in subjects with non-insulin dependent diabetes mellitus.
Ikeda T; Iwata K; Tanaka Y
Diabetes Res Clin Pract; 1999 Mar; 43(3):193-8. PubMed ID: 10369429
[TBL] [Abstract][Full Text] [Related]
32. Cardiac sympathetic neuropathy and effects of aldose reductase inhibitor in streptozotocin-induced diabetic rats.
Kurata C; Okayama K; Wakabayashi Y; Shouda S; Mikami T; Tawarahara K; Sugiyama T
J Nucl Med; 1997 Nov; 38(11):1677-80. PubMed ID: 9374332
[TBL] [Abstract][Full Text] [Related]
33. Effect of aldose reductase inhibitor on cutaneous nerve fiber length in diabetic patients.
Yasuda H; Hirai A; Joko M; Terada M; Kawabata T; Maeda K; Haneda M; Kashiwagi A; Maeda T; Kikkawa R
Diabetes Care; 2000 May; 23(5):705. PubMed ID: 10834436
[No Abstract] [Full Text] [Related]
34. Three-year inhibition of aldose reductase on development of symptomatic neuropathy in diabetic patients.
Baba M; Kimura K; Suda T; Yagihashi S;
J Peripher Nerv Syst; 2006 Jun; 11(2):176-8. PubMed ID: 16787519
[No Abstract] [Full Text] [Related]
35. Epalrestat improves diabetic wound healing via increased expression of nerve growth factor.
Nakagaki O; Miyoshi H; Sawada T; Atsumi T; Kondo T; Atsumi T
Exp Clin Endocrinol Diabetes; 2013 Feb; 121(2):84-9. PubMed ID: 23426701
[TBL] [Abstract][Full Text] [Related]
36. Long-term effects of ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensorimotor polyneuropathy.
Bril V; Buchanan RA
Diabetes Care; 2006 Jan; 29(1):68-72. PubMed ID: 16373898
[TBL] [Abstract][Full Text] [Related]
37. Aldose reductase structures: implications for mechanism and inhibition.
El-Kabbani O; Ruiz F; Darmanin C; Chung RP
Cell Mol Life Sci; 2004 Apr; 61(7-8):750-62. PubMed ID: 15095000
[TBL] [Abstract][Full Text] [Related]
38. Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study.
Hotta N; Toyota T; Matsuoka K; Shigeta Y; Kikkawa R; Kaneko T; Takahashi A; Sugimura K; Koike Y; Ishii J; Sakamoto N;
Diabetes Care; 2001 Oct; 24(10):1776-82. PubMed ID: 11574441
[TBL] [Abstract][Full Text] [Related]
39. Effect of a new aldose reductase inhibitor, (E)-3-carboxymethyl-5-[(2E)-methyl-3-phenylpropenylidene]rhodanine (ONO-2235) on peripheral nerve disorders in streptozotocin-diabetic rats.
Kikkawa R; Hatanaka I; Yasuda H; Kobayashi N; Shigeta Y; Terashima H; Morimura T; Tsuboshima M
Diabetologia; 1983 Apr; 24(4):290-2. PubMed ID: 6407887
[TBL] [Abstract][Full Text] [Related]
40. Long-term effect of epalrestat, an aldose reductase inhibitor, on the development of incipient diabetic nephropathy in Type 2 diabetic patients.
Iso K; Tada H; Kuboki K; Inokuchi T
J Diabetes Complications; 2001; 15(5):241-4. PubMed ID: 11522497
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]